School of Medicine, Endowed Research Laboratory for Arrhythmia Advanced Therapeutics Division of Cardiology, Department of Medicine (Shinanomachi)


Project Assistant Professor (Non-tenured)/Project Research Associate (Non-tenured)/Project Instructor (Non-tenured) (None)

Related Websites


Research Areas 【 Display / hide

  • Cardiovascular medicine (Heart Failure)

  • Cardiovascular medicine (Clinical Research)

Research Keywords 【 Display / hide

  • Heart Failure

  • Clinical Research


Papers 【 Display / hide

  • Time-Sensitive Approach in the Management of Acute Heart Failure

    Shiraishi Y., Kawana M., Nakata J., Sato N., Fukuda K., Kohsaka S.

    ESC Heart Failure (ESC Heart Failure)  8 ( 1 ) 204 - 221 2020

    Research paper (scientific journal), Accepted

     View Summary

    Acute heart failure (AHF) has become a global public health burden largely because of the associated high morbidity, mortality, and cost. The treatment options for AHF have remained relatively unchanged over the past decades. Historically, clinical congestion alone has been considered the main target for treatment of acute decompensation in patients with AHF; however, this is an oversimplification of the complex pathophysiology. Within the similar clinical presentation of congestion, significant differences in pathophysiological mechanisms exist between the fluid accumulation and redistribution. Tissue hypoperfusion is another vital characteristic of AHF and should be promptly treated with appropriate interventions. In addition, recent clinical trials of novel therapeutic strategies have shown that heart failure management is ‘time sensitive’ and suggested that treatment selection based on individual aetiologies, triggers, and risk factor profiles could lead to better outcomes. In this review, we aim to describe the specifics of the ‘time-sensitive’ approach by the clinical phenotypes, for example, pulmonary/systemic congestion and tissue hypoperfusion, wherein patients are classified based on pathophysiological conditions. This mechanistic classification, in parallel with the comprehensive risk assessment, has become a cornerstone in the management of patients with AHF and thus supports effective decision making by clinicians. We will also highlight how therapeutic modalities should be individualized according to each clinical phenotype.

  • Derivation and Validation of Clinical Prediction Models for Rapid Risk Stratification for Time-Sensitive Management for Acute Heart Failure.

    Shiraishi Y, Kohsaka S, Abe T, Nagai T, Goda A, Nishihata Y, Nagatomo Y, Saji M, Toyosaki Y, Takei M, Kitai T, Kohno T, Fukuda K, Matsue Y, Anzai T, Yoshikawa T

    Journal of Clinical Medicine 9 ( 11 )  2020.10

    Research paper (scientific journal), Accepted


  • Benefit and harm of intravenous vasodilators across the clinical profile spectrum in acute cardiogenic pulmonary oedema patients

    Shiraishi Y, Kohsaka S, Katsuki T, Harada K, Miyazaki T, Miyamoto T, Matsushita K, Iida K, Takei M, Yamamoto Y, Shindo A, Kitano D, Nagatomo Y, Jimba T, Yamamoto T, Nagao K, Takayama M, for Tokyo CCU Network Scientific Committee.

    European Heart Journal: Acute Cardiovascular Care 9 ( 5 ) 2048872619891075 - 458 2020.01

    Research paper (scientific journal), Accepted,  ISSN  2048-8726

  • Impact of tacrolimus versus cyclosporin A on renal function during the first year after heart transplant

    Shiraishi Y, Amiya E, Hatano M, Katsuki T, Bujo C, Tsuji M, Nitta D, Maki H, Ishida J, Kagami Y, Endo M, Kimura M, Ando M, Shimada S, Kinoshita O, Ono M, Komuro I

    ESC Heart Failure (ESC Heart Failure)  7 ( 4 ) 1842 - 1849 2020.05

    Research paper (scientific journal), Accepted

     View Summary

    Aims: Nephrotoxicity of calcineurin inhibitors (CNIs) is associated with adverse events in patients undergoing heart transplant (HTx), although studies directly comparing tacrolimus (TAC) versus cyclosporin A (CsA), especially in combination with everolimus and low-dose CNIs approach, are limited. Thus, we sought to investigate the associations of TAC and CsA with clinical outcomes in HTx recipients, with specific focus on renal function. Methods and results: From August 2007 to February 2017, 72 consecutive patients (39 treated with TAC vs. 33 with CsA) receiving de novo HTx in a single transplant centre were retrospectively evaluated. We used the instrumental variable method to account for unmeasured confounding. The study outcomes were percentage change in estimated glomerular filtration rates (eGFR) (safety endpoint) and biopsy-proven acute rejection (efficacy endpoint) within the first year after HTx. The enrolled patients (median age 40 years) were predominantly men (68%). There were no significant differences in baseline characteristics, including eGFR (64.8 [45.7–96.4] mL/min/1.73 m2 in TAC vs. 65.6 [57.9–83.0] mL/min/1.73 m2 for CsA; P = 0.48), other than sex (male, 49% for TAC vs. 91% for CsA; P < 0.001) between the two groups. Within the first year after HTx, 23 (59%) in the TAC group switched mycophenolate mofetil to everolimus, whereas 16 (48%) in the CsA group (P = 0.52). At 12 months, the rates of mortality and end-stage renal disease requiring renal replacement therapies were both 0%. In the instrumental variable analysis, no differences in renal function as well as graft rejection for 1 year after HTx existed between the TAC and CsA groups. These results were similar when taking into account of everolimus use. Conclusions: Irrespective of everolimus use with low-dose CNIs, our analysis using the instrumental variable method showed no differences in renal function as well as graft rejection during the first year after HTx between HTx recipients who received TAC or CsA.


  • 9-year Trend in the Management of Acute Heart Failure in Japan: A Report from the National Consortium of Acute Heart Failure Registries

    Shiraishi Y., Kohsaka S., Sato N., Takano T., Kitai T., Yoshikawa T., Matsue Y.

    Journal of the American Heart Association (Journal of the American Heart Association)  7 ( 18 ) e008687 2018.09

    Research paper (scientific journal), Accepted

     View Summary

    © 2018 The Authors. Background-—Acute heart failure (AHF) is a heterogeneous condition, and its characteristics and management patterns differ by region. Furthermore, limited evidence is available on AHF outside of Western countries. A project by the National Consortium of Acute Heart Failure Registries was designed to evaluate the trends over time in patient backgrounds, in-hospital management patterns, and long-term outcomes of patients with AHF over 9 years in Japan. Methods and Results-—Between 2007 and 2015, registry data for patients with AHF were collected from 3 large-scale quality AHF registries (ATTEND/WET-HF/REALITY-AHF). Predefined end points were trends over time in age, sex, and clinical outcomes, including short- and long-term mortality and readmission for heart failure. The final data set consisted of 9075 patients with AHF. No significant differences in patient backgrounds and laboratory findings (eg, anemia or renal function) were observed, with the exception of patient age; mean age became substantially higher over 9 years (71.6–77.0 years; P for trend, <0.001). On the contrary, length of hospital stay became shorter (mean, 26–16 days). These changes were not associated with in-hospital mortality (4.7–7.5%) or 30-day heart failure readmission rate (4.8–5.4%), as well as 1-year mortality and heart failure readmission rate (20.1– 23.3% and 23.6–26.2%, respectively). Conclusions-—Length of hospital stay in patients with AHF shortened over the 9-year period despite the increasing age of the patients. However, short- and long-term outcomes do not seem to be affected; continuous efforts to monitor clinical outcomes in patients with AHF are needed.

display all >>

Reviews, Commentaries, etc. 【 Display / hide

  • 【プライマリ・ケア医が知っておくべき心不全診療】診断 心不全の症状と身体所見

    白石 泰之

    治療 ((株)南山堂)  102 ( 6 ) 658 - 660 2020.06

    ISSN  0022-5207

  • 【いつ手術・インターベンションに送るの? 今でしょ! 今じゃないでしょ! 今のジョーシキ![循環器・消化器・神経疾患編]】循環器疾患(冠動脈疾患・心不全)

    新美 望, 白石 泰之, 香坂 俊

    総合診療 ((株)医学書院)  30 ( 2 ) 146 - 155 2020.02

    ISSN  2188-8051

  • 【内科学書(改訂第9版)】薬物性・医原性疾患

    白石 泰之, 佐野 元昭

    内科学書 (中山書店)   2019.08

    ISSN  978-4-521-74749-1

  • 【心不全(第2版)上 -最新の基礎・臨床研究の進歩-】 疫学 コホート研究 日本におけるコホート研究:WET-HF研究

    白石 泰之, 香坂 俊

    日本臨床 ((株)日本臨床社)  76 ( 増刊9 心不全(上) ) 76 - 82 2018.12

    ISSN  0047-1852

  • 【心不全】(Part 1)総論 心不全の疫学, 心不全予後予測スコアとその使い方 効果的かつ効率的な医療を実践するために

    白石 泰之

    Hospitalist ((株)メディカル・サイエンス・インターナショナル)  6 ( 4 ) 793 - 805 2018.12

    ISSN  2188-0409

     View Summary

    <文献概要>Summary ●心不全患者数は向こう10〜20年間は増加の一途をたどり,さらに患者の高齢化が劇的に進んでいる。日本の心不全患者の入院期間は依然として世界標準よりも長いが(15日前後),長期予後は欧米諸国に比べると良好である。●年齢や血圧,尿素窒素,血中ナトリウム濃度,そしてBNP/NT-proBNP値などが心不全患者における単独の強力な予後予測因子である。●心不全リスクモデルのなかで,GWTG-HF Risk ScoreあるいはSeattle Heart Failure Model, MAGGIC Heart Failure Risk Scoreは,日本人における当てはまりが確認されており,実際に臨床現場で使用することも可能である。●いかに熟練の医師といえども,心不全患者の予後予測は困難な場合も多く,リスクモデルによる客観的な予後予測は有用である。予後予測(リスク評価)は医療者,患者の治療方針あるいは意思決定の支柱であり,効果的かつ効率的な医療の実践のためには,リスクモデルを用いた評価が不可欠である。

display all >>

Presentations 【 Display / hide

  • カルシニューリン阻害薬の心移植後腎機能へ与える影響:タクロリムスとシクロスポリンの比較

    白石 泰之, 網谷 英介, 波多野 将, 勝木 俊臣, 武城 千恵, 辻 正樹, 牧 尚孝, 石田 純一, 細谷 弓子, 遠藤 美代子, 木村 光利, 木下 修, 小野 稔, 小室 一成

    第55回日本移植学会総会, 2019.10, Poster (general)

  • 慢性心不全看護認定看護師の役割と将来像:心不全外来における看護師の役割

    中野 直美, 志村 千尋, 河野 隆志, 白石 泰之

    第67回日本心臓病学会学術集会, 2019.09, Symposium, Workshop, Panelist (nomination)

  • HFpEF診療における治療ターゲットを再考する -HFpEFの疾患プロセスにおける左室リモデリングとは-

    長友 祐司, 小川 翔, 合田 あゆみ, 筋野 容守, 水野 篤, 白石 泰之, 河野 隆志, 香坂 俊, 吉川 勉

    第67回日本心臓病学会学術集会, 2019.09, Symposium, Workshop, Panelist (public offering)

  • Prehospital Evaluation and Management in Patients with Acute Heart Failure

    Shiraishi Yasuyuki, Kohsaka Shun, Yamamoto Takeshi, Nagao Ken, Takayama Morimasa, Fukuda Keiichi

    第83回日本循環器学会学術集会, 2019.03, Symposium, Workshop, Panelist (nomination)

  • Guideline-based Medical Therapy and Its Prognostic Impact in Elderly Patients Admitted with Acute Heart Failure with Reduced Ejection Fraction

    秋田 敬太郎, 河野 隆志, 香坂 俊, 白石 泰之, 長友 祐司, 合田 あゆみ, 水野 篤, 吉川 勉

    第83回日本循環器学会学術集会, 2019.03, Symposium, Workshop, Panelist (public offering)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 画像情報と深層学習を応用した心疾患患者の予後予測と革新的な治療戦略の開発


    上原記念生命科学財団, 研究奨励金(新領域 4.0), 白石 泰之, Research grant, Principal Investigator

  • Telemedicine Using Multi-Dementional Biological Sensors Information and Communication Technology in Combination With Artificial Intelligence


    公益財団法人セコム科学技術振興財団, 挑戦的研究助成, Yasuyuki Shiraishi, Research grant, Principal Investigator

  • 第二世代急性心不全患者予後予測システムの構築:画像情報とその深層学習の応用


    日本循環器学会, 医師臨床研究助成, 白石 泰之, Research grant, Principal Investigator

  • 生体センサを活用した心不全患者のための「こころと眠りの支援プログラム」開発と評価


    Keio University, 野末 聖香, 久保 美紀, 佐藤 雅明, 福田 紀子, 河野 隆志, 田久保 美千代, 白石 泰之, 吉永 新子, Grant-in-Aid for Scientific Research (B)

     View Summary


  • ウェアラブル端末を用いた効果的な心不全診療実践のための探索的研究


    MEXT,JSPS, Grant-in-Aid for Scientific Research, 白石 泰之, Grant-in-Aid for Early-Career Scientists , Principal Investigator

     View Summary

    当研究の母体となる多施設合同急性心不全レジストリ(West Tokyo Heart Failure Registry 2)の登録者数は現在500人(2018年4月から2019年3月)とEDC(electronic data capturing system)上へのデータ入力は比較的順調に進んでおり、これら患者全例において前述の①在宅環境や社会サポートの状況につき今後詳細な検討を行う。②については現在100~150名程度で評価しており、こちらも今後詳細な検討を計画している。③在宅での症状やQoL・活動度については、ウェアラブル端末での評価を実施した被験者数はまだ十分でなく、引き続き被験者登録を継続していく予定である。


Memberships in Academic Societies 【 Display / hide

  • 欧州心臓病学会, 

  • 日本心臓リハビリテーション学会, 

  • 日本心不全学会, 

  • 日本心臓病学会, 

  • 日本循環器学会, 


display all >>